Application of STAT3 biphosphorylation inhibitor in preparation of medicine for preventing or treating triple negative breast cancer

Pulsatilla saponin E2, as a STAT3 diphosphorylation inhibitor, solves the problems of poor efficacy and severe toxic side effects of triple-negative breast cancer drugs by inhibiting phosphorylation at Tyr705 and Ser727 sites of STAT3 protein, achieving a highly effective and low-toxicity therapeutic effect.

CN118873545AActive Publication Date: 2024-11-01SOUTHWEST MEDICAL UNIV

Patent Information

Application Number
CN202410898381.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-05
Publication Date
2024-11-01
Estimated Expiration
2044-07-05

Smart Images

  • Figure CN118873545A_ABST
    Figure CN118873545A_ABST
Patent Text Reader

Abstract

The invention provides an application of an STAT3 diphosphorylation inhibitor in preparation of a medicine for preventing or treating triple negative breast cancer, and belongs to the technical field of biological medicine, and the STAT3 diphosphorylation inhibitor comprises pulsatilla saponin E2 and / or pharmaceutically acceptable salt thereof. The pulsatilla saponin E2, as an STAT3 biphosphorylation inhibitor, can effectively inhibit growth and migration of triple negative breast cancer cells, and has the advantages of good curative effect and small toxic and side effects when being applied to treatment of triple negative breast cancer.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine technology, and particularly relates to the use of a STAT3 dual phosphorylation inhibitor in the preparation of a drug for preventing or treating triple-negative breast cancer. Background Art

[0002] Triple negative breast cancer (TNBC) is a poorly differentiated subtype of breast cancer, characterized by the loss of progesterone receptor, human epidermal growth factor receptor 2, and estrogen receptor expression. High invasiveness and lack of drug targets have always been important factors affecting the prognosis of TNBC patients. The five-year survival rate after the first surgery is only 40%, and the five-year survival rate of advanced patients is less than 20%, which seriously threatens people's daily life. In foreign countries, TNBC tends to be younger, and almost all deaths in patients are caused by the malignant progression of TNBC. In my country, the high-incidence age of TNBC is between 40 and 70 years old. When first diagnosed, most patients have already shown distant metastasis and have a very poor prognosis. Recently, chemotherapy drugs, antibody-drug conjugates, immunotherapy, and targeted therapy drugs are often used in clinical treatment of TNBC, but patients still experience little efficacy and serious toxicity and side effects. In order to reduce the malignant progression of TNBC and improve the prognosis of patients, it is necessary to find and develop new anti-TNBC drugs with high efficiency, low toxicity and important value.

[0003] Targeting signal transducer and activator of transcription 3 (STAT3) has become a hot topic in the development of anti-tumor drugs. Studies have shown that the activation of STAT3 is mainly attributed to the phosphorylation of two key amino acid residues, namely, tyrosine 705 (Tyr 705 ) and Ser 727 727 ). Normally, STAT3 is activated by JAK and other tyrosine kinases through its SH2 domain to catalyze the cleavage of Tyr 705 STAT3 is activated by phosphorylation, which leads to STAT3 dimerization and nuclear translocation, thereby regulating target gene expression and transcription. 727 The site is phosphorylated by several serine kinases, leading to another form of STAT3 activation. Tyr705 Typical role of phosphorylation, STAT3 Ser727 Phosphorylation mainly regulates its mitochondrial function, thereby affecting the metabolic reprogramming of tumor cells. 705 and Ser 727 Therefore, the phosphorylation of Tyr 705 and Ser 727Dual phosphorylation sites can block STAT3 activation, which may be a promising strategy for STAT3 target drug development. Summary of the invention

[0004] In order to solve the problem of poor efficacy and serious toxic and side effects of existing TNBC drugs, the present invention provides the use of a STAT3 dual phosphorylation inhibitor in the preparation of a drug for preventing or treating triple-negative breast cancer. The dual phosphorylation inhibitor is pulsatilla saponin E2, which can effectively inhibit the growth and migration of triple-negative breast cancer cells. It is applied to the treatment of triple-negative breast cancer, and has the advantages of good efficacy and small toxic and side effects.

[0005] The present invention is achieved through the following technical solutions:

[0006] The present invention provides an application of a STAT3 dual phosphorylation inhibitor in the preparation of a drug for preventing or treating triple-negative breast cancer. The STAT3 dual phosphorylation inhibitor comprises scutellariae saponin E2 and / or a pharmaceutically acceptable salt thereof. The structural formula of scutellariae saponin E2 is as follows:

[0007]

[0008] Based on the same inventive concept, the present invention provides the use of pulsatilla saponin E2 and / or its pharmaceutically acceptable salt as a STAT3 dual phosphorylation inhibitor in the preparation of a drug for inhibiting the growth or metastasis of triple-negative breast cancer cells.

[0009] Based on the same inventive concept, the present invention provides a novel saponin E2 and / or a pharmaceutically acceptable salt thereof in inhibiting STAT3 protein Tyr 705 and / or Ser 727 Application in phosphorylation.

[0010] Based on the same inventive concept, the present invention provides the use of Pulsatilla saponin E2 and / or its pharmaceutically acceptable salt in inhibiting STAT3 nuclear transcription and / or STAT3-dependent mitochondrial oxidative phosphorylation.

[0011] Based on the same inventive concept, the present invention provides the use of Pulsatilla saponin E2 and / or its pharmaceutically acceptable salt as and / or in the preparation of a STAT3 dual phosphorylation inhibitor.

[0012] Furthermore, the STAT3 dual phosphorylation inhibitor includes inhibiting STAT3 protein Tyr 705 and Ser 727 Reagents for phosphorylation of sites.

[0013] Based on the same inventive concept, the present invention provides a drug for preventing or treating triple-negative breast cancer, wherein the active ingredient of the drug includes pulsatilla saponin E2 and / or a pharmaceutically acceptable salt thereof.

[0014] Based on the same inventive concept, the present invention provides a drug for inhibiting the growth or metastasis of triple-negative breast cancer cells, wherein the active ingredient of the drug includes pulsatilla saponin E2 and / or a pharmaceutically acceptable salt thereof.

[0015] Based on the same inventive concept, the present invention provides a STAT3 dual phosphorylation inhibitor, wherein the active ingredient of the STAT3 dual phosphorylation inhibitor includes pulsatilla saponin E2 and / or a pharmaceutically acceptable salt thereof.

[0016] Furthermore, the STAT3 dual phosphorylation inhibitor includes inhibiting STAT3 protein Tyr 705 and Ser 727 Reagents for phosphorylation of sites.

[0017] One or more technical solutions in the embodiments of the present invention have at least the following technical effects or advantages:

[0018] 1. The use of the STAT3 dual phosphorylation inhibitor of the present invention in the preparation of drugs for preventing or treating triple-negative breast cancer. The present invention first discovered that pulsatilla saponin E2 can be used as a STAT3 dual phosphorylation inhibitor, significantly inhibiting the expression of STAT3 protein Tyr 705 Phosphorylation and nuclear transcription of STAT3 significantly inhibited STAT3 protein Ser 727 Phosphorylation and STAT3-dependent mitochondrial oxidative phosphorylation, PSE2 (Pulchinenoside E2) as a STAT3 dual phosphorylation inhibitor, can take STAT3 as the core target, effectively inhibit the growth and migration of TNBC cells, thereby achieving the prevention or treatment of triple-negative breast cancer. PSE2 can be used as a drug for the prevention and treatment of triple-negative breast cancer, with the advantages of good efficacy and less toxic side effects.

[0019] 2. The use of Pulsatilla saponin E2 and / or its pharmaceutically acceptable salt as a STAT3 dual phosphorylation inhibitor in the preparation of a drug for inhibiting the growth or metastasis of triple-negative breast cancer cells. The STAT3 dual phosphorylation inhibitor PSE2 or its pharmaceutically acceptable salt is used as a drug for inhibiting the growth or metastasis of TNBC cells, and can simultaneously act on the STAT3 protein Tyr 705 and Ser 727 Phosphorylation site, significantly inhibiting Tyr 705 and Ser 727 It phosphorylates STAT3 and inhibits STAT3 transcriptional activity and mitochondrial STAT3-dependent oxidative phosphorylation, and shows the strongest activity in the screening of drug efficacy for inhibiting the growth and migration of triple-negative breast cancer cells, suggesting that PSE2 provides a promising candidate lead compound for the development of drugs to inhibit the growth or metastasis of TNBC, and has broad development and application prospects. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] In order to more clearly illustrate the technical solutions in the embodiments of the present invention, the following briefly introduces the drawings required for use in the description of the embodiments. Obviously, the drawings described below are some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without creative work.

[0021] Figure 1 This is a diagram for drug efficacy screening on TNBC cell growth and migration.

[0022] Figure 2 STAT3 is a direct core target of PSE2.

[0023] Figure 3 PSE2 can stably bind to STAT3 protein.

[0024] Figure 4 These are the key target screening results for PSE2 against TNBC cell invasion and migration.

[0025] Figure 5 PSE2 significantly inhibited p-STAT3 (Tyr 705 ) and STAT3 nuclear transcription.

[0026] Figure 6 PSE2 inhibits p-STAT3 (Ser 727 ) and mitochondrial STAT3-dependent oxidative phosphorylation.

[0027] Figure 7 PSE2 effectively inhibits lung and liver metastasis of TNBC in mice. DETAILED DESCRIPTION

[0028] The present invention will be described in detail below in conjunction with specific implementations and examples, and the advantages and various effects of the present invention will be more clearly presented. It should be understood by those skilled in the art that these specific implementations and examples are used to illustrate the present invention, rather than to limit the present invention.

[0029] Throughout the specification, unless otherwise specifically stated, the terms used herein should be understood as meanings commonly used in the art. Therefore, unless otherwise defined, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art to which the present invention belongs. In the event of a conflict, the present specification takes precedence.

[0030] Unless otherwise specified, various raw materials, reagents, instruments and equipment used in the present invention can be purchased from the market or prepared by existing methods.

[0031] The technical principle of the present invention is as follows:

[0032] Pulsatilla chinensis (Bge.) Regel is a perennial herbaceous plant of the Ranunculaceae family, distributed in East Asia, especially in Jilin, Liaoning, Heilongjiang, Hebei, Shandong and other places in China. 53 H 86 O 21 ) is a saponin compound isolated from Pulsatilla chinensis. The present invention first discovered that: 1) PSE2, as the chemical component of Pulsatilla chinensis that exerts the main pharmacological effect, exhibits the strongest activity in the pharmacological screening of inhibiting TNBC cell migration; 2) STAT3 is the core target of PSE2 in combating TNBC cell metastasis; 3) PSE2 significantly inhibits p-STAT3 Tyr705 and STAT3 nuclear transcription; 4) PSE2 inhibits p-STAT3 Ser727 and mitochondrial oxidative phosphorylation; 5) PSE2 can effectively inhibit the lung and liver metastasis of TNBC in mice.

[0033] Based on this, the present invention proposes for the first time the use of PSE2 as a STAT3 dual phosphorylation inhibitor in the preparation of drugs for the prevention or treatment of triple-negative breast cancer. The present invention proves through experiments that PSE2, as the chemical component of Pulsatilla that exerts the main efficacy, shows the strongest activity in the screening of pharmacodynamics for inhibiting the growth and migration of TNBC cells. Compared with MCF-10A and MCF-7 cells, PSE2 is more selective in inhibiting the migration of MDA-MB-231 cells. Through network pharmacology, molecular docking, molecular dynamics and cellular thermal shift assay (Cellular Thermal Shift Assay, CETSA), the present invention found that STAT3 is a direct core target, and PSE2 directly forms hydrogen bonds with multiple amino acid residues in the STAT3-SH2 domain, and the PSE2-STAT3 complex has good stability. Transwell results show that PSE2 significantly hinders the invasion and migration of TNBC cells; after knocking down STAT3, the inhibitory effect of PSE2 is weakened. Therefore, STAT3 is likely to be the direct core target of PSE2 to exert its anti-TNBC metastasis effect. Mechanistically, it was found that PSE2 significantly inhibited STAT3 (Tyr 705 ) and STAT3 (Ser 727 ) phosphorylation, inhibiting STAT3 transcriptional activity and mitochondrial STAT3-dependent oxidative phosphorylation. Animal experiments confirmed that PSE2 significantly inhibited the lung and liver metastasis of triple-negative breast cancer in mice. This suggests that PSE2 provides a promising candidate lead compound for the development of anti-triple-negative breast cancer metastasis drugs, with broad development and application prospects.

[0034] The application of the STAT3 dual phosphorylation inhibitor of the present application in the preparation of drugs for preventing or treating triple-negative breast cancer will be described in detail below in combination with examples and experimental data.

[0035] Example 1

[0036] This example performs drug efficacy screening on TNBC cell growth and migration.

[0037] The experimental method is as follows:

[0038] First, the network pharmacology method was used to screen the active ingredients of Pulsatilla striata, the corresponding targets of the active ingredients of the drugs were collected in the drug target database, the corresponding targets of TNBC metastasis were screened in the disease database, and the "Pulsatilla striata-active ingredients-targets-TNBC metastasis" interaction network was drawn to predict the potential role of the chemical component groups that exert the main anti-tumor efficacy of Pulsatilla striata in TNBC metastasis. Subsequently, the cell activity and migration ability of the above-mentioned putative effective compounds of Pulsatilla striata were verified by MTT and Transwell methods, respectively. Finally, the Transwell method was used to detect the effect of PSE2 on the migration of TNBC cells (MDA-MB-231), breast cancer cells (MCF-7) and normal breast epithelial cells (MCF-10A), highlighting the selectivity of PSE2 on TNBC cell migration.

[0039] 1. Network pharmacology predicts the chemical components of Pulsatilla striata that exert the main anti-tumor effects:

[0040] Network pharmacology was used to collect as many Pulsatilla components as possible from the TCMSP database (https: / / old.tcmsp-e.com / tcmsp.php) and literature, and the druglikeness (DL, drugability) ≥ 0.18 was used as the standard to screen the active ingredients of Pulsatilla, and the active ingredients reported in the literature were combined. Subsequently, the targets corresponding to the active ingredients of drugs were collected in the TCMSP, Super-PRED (https: / / prediction.charite.de / subpages / target_prediction.php), Swiss TargetPrediction (STP, http: / / swisstargetprediction.ch / ) and PharmMapper (http: / / www.lilab-ecust.cn / pharmmapper / ) online databases, and the targets corresponding to TNBC metastasis were screened using the GeneCards database. The "Pulsatilla-active ingredient-target-TNBC metastasis" interaction network was drawn using Cytoscape3.10.1 software to predict the potential role of the active ingredients of Pulsatilla in TNBC metastasis.

[0041] 2. MTT method to verify the cell activity of effective compounds of Pulsatilla truncatula:

[0042] MDA-MB-231 cells were inoculated in a 96-well plate and incubated overnight in a cell culture incubator at 37°C. 0-4 μM of the above-mentioned effective compounds of Pulsatilla were added to each well for 48 hours, and 10 uL of MTT solution was added for further incubation for 4 hours. The supernatant was discarded, 100 uL of DMSO was added, the microplate was shaken and mixed, and the OD value of each well was detected at 570 nm using an enzyme reader.

[0043] 3. Transwell method to verify the cell migration of effective compounds of Pulsatilla truncatula:

[0044] MDA-MB-231 cells were seeded in the upper chamber of the Transwell nesting, and 0-0.5 μM of the above-mentioned effective compound of Pulsatilla dasyphylla was added to the lower chamber for treatment for 12 hours. The chamber was removed, fixed with 4% paraformaldehyde, stained with crystal violet, and the migrating cells were counted and photographed under a light microscope.

[0045] 4. Transwell assay to detect the selectivity of PSE2 on TNBC cell migration:

[0046] MDA-MB-231 cells were seeded in the upper chamber of the Transwell nest, and 0-1.0 μM PSE2 was added to the lower chamber for treatment for 24 h. The chamber was removed, fixed and stained with crystal violet, and the number of migrated cells was counted under a light microscope and photographed.

[0047] The experimental results are as follows:

[0048] Using network pharmacology methods, 58 Pulsatilla components were collected from the TCMSP database and published literature as much as possible. The active ingredients of Pulsatilla were screened with DL ≥ 0.18 as the standard. Combined with the active ingredients in the literature, 25 active ingredients of Pulsatilla were finally obtained ( Figure 1 A). The targets corresponding to the active ingredients of drugs were collected from the TCMSP database and SwissTargetPrediction platform, and 5877 TNBC metastasis-related genes were obtained from the GeneCards disease database. The "Pulsatilla-active ingredient-target-TNBC metastasis" network was constructed using Cytoscape software ( Figure 1 A), in order to predict the potential role of the active ingredients of Pulsatilla in TNBC metastasis. At the cellular level, the inhibitory effects of these 25 active ingredients of Pulsatilla on MDA-MB-231 cell proliferation and migration were further explored. The results showed that saponin active ingredients (PSE2, PSE4, etc.) are the main chemical component group of Pulsatilla that exerts anti-proliferation and migration effects ( Figure 1 B-1C). PSE2 is the main chemical component of Pulsatilla truncatula that exerts its pharmacological effects in inhibiting cell growth (IC 50 =1.05μM 48h) and migration (inhibition rate 11.35%, 0.5μM PSE2, 12h) showed the strongest activity in the efficacy screening ( Figure 1 B-1C). In addition, compared with MCF-10A and MCF-7 cells, PSE2 was more selective in inhibiting the migration of MDA-MB-231 cells (P<0.05) ( Figure 1 D).

[0049] Figure 1The figure is a drug screening diagram for TNBC cell growth and migration. A: Cytoscape3.10.1 software constructed the network diagram of Pulsatilla-active ingredients-target-TNBC metastasis: the triangular nodes represent the active ingredients in Pulsatilla; the elliptical nodes represent the presumed targets of Pulsatilla for TNBC. B: The MTT method was used to verify the MDA-MB-231 cell activity of the above 25 putative 0-4μM Pulsatilla effective compounds: *P<0.05, **P<0.01, compared with the control group (0μM without drug treatment). C: Transwell method was used to verify the MDA-MB-231 cell migration of the above 25 putative 0-0.5μM Pulsatilla effective compounds: *P<0.05, **P<0.01, compared with the control group (0μM without drug treatment). D: Transwell assay to detect the effect of 0-3 μM PSE2 on the migration of MDA-MB-231, MCF-7 and MCF-10A cells: **P<0.01, compared with the MDA-MB-231 group. Among them: 1. Pinoresinol, 2. Sophora flavescens, 3. Korean scutellaria baicalensis glycoside, 4. Antirrhinol, 5. Lanosterol, 6. Podophyllotoxin, 7. β-Sitosterol, 8. Isochelolide, 9. Betulinic acid, 10. Tricosanoic acid, 11. Oleanolic acid, 12. Ergosterol, 13. Isorhamnetin, 14. Sitoside, 15. Stigmasterol, 16. Ursolic acid, 17. Ligusticum glabra saponin B4, 19. Scutellaria baicalensis saponin A, 20. Scutellaria baicalensis saponin E2, 21. Scutellaria baicalensis saponin E4, 22. Hydroxybetulinic acid, 23. Viburnum scutellaria saponin A, 24. β-Sitosterol acetate, 25. Hederagenin.

[0050] Example 2

[0051] This example explores the core target of PSE2 in combating TNBC cell metastasis.

[0052] The experimental method is as follows:

[0053] The network pharmacology method was used to collect PSE2 corresponding targets and TNBC metastasis-related targets. The common targets were obtained by intersecting the two. The Centi scape2.2 plug-in in the Cytoscape software was used to set the threshold to further determine the core targets. Molecular docking was used to compare and predict the most direct core target of PSE2 (STAT3). Molecular dynamics simulation was used to detect the binding mode of PSE2 and STAT3. CETSA experiment was used to detect the binding stability of PSE2 and STAT3 protein. After knocking down STAT3, the Transwell method was used to verify that STAT3 was the key target of PSE2 in resisting TNBC cell invasion and migration.

[0054] 1. Network pharmacology predicts the core targets of PSE2 in treating TNBC metastasis:

[0055] Network pharmacology was used to collect PSE2-related targets in the Super-PRED, STP, and PharmMapper online databases, and GeneCards database was used to screen TNBC metastasis-related targets. The two were intersected to obtain common targets. The Centiscape2.2 plug-in in Cytoscape software was used to set thresholds to further determine core targets.

[0056] 2. Molecular docking to screen the targets of PSE2:

[0057] The crystal structures corresponding to 11 core targets were obtained using AlphaFold2 or RCSB PDB databases. The protein crystals obtained were processed by protein preparation wizard module of Schrödinger software for protein preprocessing, regenerate states of native ligand, H-bond assignment optimization, protein energy minimization and waters removal. The best binding site was predicted by SiteMap module in Schrödinger, and the most appropriate Enclosingbox was set by Receptor Grid Generation module in Schrödinger to perfectly encapsulate the predicted binding site, and the active sites of 11 proteins were obtained on this basis. The treated ligand compound PSE2 was molecularly docked with the active sites of 11 proteins, and the MM-GBSA binding free energy was calculated and analyzed.

[0058] 3. Molecular dynamics simulation to detect the binding mode of PSE2 and STAT3:

[0059] The OPLS4 force field was used to parameterize proteins and small molecules, and the SPCE model was used to parameterize water solvents to perform molecular dynamics simulations. The docked complex was simulated unrestricted for 100 ns, and Maestro 2023 was used to analyze the interaction and generate dynamic trajectory animations to obtain the root mean square deviation (RMSD) graph, root mean square fluctuation (RMSF) graph, stable binding mode, and the changes in the interaction between PSE2 and specific amino acids of STAT3 protein over time.

[0060] 4. CETSA method to detect the binding of PSE2 and STAT3 protein:

[0061] When TNBC cells grew to 80%, they were treated with 0.75 μM PSE2 or DMSO for 1 h. The cells were collected and suspended in PBS containing PMSF and phosphatase inhibitors, and then divided into 0.2 mL centrifuge tubes, 100 μL / tube. Each tube was heated to the specified temperature point for 2 min, immediately removed after heating, cooled to room temperature, and frozen in liquid nitrogen. To lyse the cells, each tube was subjected to three freeze-thaw cycles in liquid nitrogen, and the cell lysate was centrifuged at 20,000 g at 4°C for 20 min. Finally, the STAT3 protein level in the cell lysate was detected by Western blot.

[0062] 5. Transwell assay to detect cell invasion and migration:

[0063] TNBC cells with stable knockdown of STAT3 were seeded in the upper chamber of a Transwell nested with Matrigel, and 0.75 μM PSE2 was added or not in the lower chamber for 24 h. The chamber was removed, fixed with 4% paraformaldehyde, stained with crystal violet, and the number of invasive cells was counted and photographed under a light microscope. The cell migration experiment was performed without Matrigel, and the method was the same as above.

[0064] The experimental results are as follows:

[0065] In order to find the direct target of PSE2 in treating TNBC metastasis, the 97 potential PSE2 targets collected were intersected with 2000 TNBC metastasis-related targets to obtain 41 common targets ( Figure 2 A). Using the network pharmacology method, the Centiscape2.2 plug-in of Cytoscape software was used to set the Closeness unDir, Betweenness unDir and Degree unDir thresholds to identify 11 key target genes (STAT3, JUN, MMP9, HSP90AA1, FGF2, KDR, IL2, ACE, PTPRC, ITGAV, NR3C1) ( Figure 2 B) The crystal structures corresponding to these 11 proteins were molecularly docked with PSE2, and it was found that STAT3 had the lowest binding free energy (kcal / mol = -28.62) ( Figure 2 C), indicating the highest binding stability. In addition, PSE2 penetrates deep into the active pocket of STAT3, and the residue MET of STAT3 660 ,ILE 659 etc. form hydrophobic interactions with PSE2, and PSE2 and residue GLU 625 LYS 626 Each forms a hydrogen bond, suggesting that STAT3 is likely to be a direct core target ( Figure 2D). Molecular dynamics simulation found that the PSE2-STAT3 complex has a small RMSF fluctuation and a stable RMSD value, indicating that the PSE2-STAT3 complex has good stability ( Figure 3 A) From the interaction trajectory between PSE2 and specific amino acids of STAT3 protein, it can be seen that the amino acid residue GLU in the STAT3-SH2 domain 625 LYS 626 GLN 635 SER 636 , GLU 638 TYR 657 LYS 658 , MET 660 There are multiple contacts with PSE2 ( Figure 3 B). Figure 3 C shows the interactions that occurred for more than 10.0% of the simulation time (i.e., the interaction time exceeded 10 ns in 100 ns) in the selected trajectory. The results show that PSE2 interacts with the amino acid residue TYR of the STAT3 protein A chain. 657 (35%), MET 660 (26% and 28%), SER 636 (14%), GLN 635 (20%), LYS 626 (24% and 20%) directly form hydrogen bonds, form one hydrogen bond within the molecule (94%), and also form a hydrogen bond with LYS 658 , TRP 623 , GLU 625 , ASP 627 The water bridge is formed (the simulation time can be used to quantitatively evaluate the stability or strength of the interaction). CETSA experiments showed that 0.75 μM PSE2 prevented the thermal denaturation of STAT3 protein, revealing that PSE2 can target and bind to STAT3 protein at the cellular level ( Figure 3 D). Transwell results showed that 0.75 μM PSE2 significantly inhibited the invasion and migration of TNBC cells (P<0.05); after knocking down STAT3, the inhibitory effect of PSE2 was weakened (P<0.05) ( Figure 4 A-4B). Therefore, STAT3 is likely to be the core target of PSE2 in exerting its anti-TNBC effect.

[0066] from Figure 2 It can be seen that STAT3 is the direct core target of PSE2. Figure 2A: Venn diagram showing the common genes after overlapping TNBC metastasis-related genes and PSE2 target genes predicted in network pharmacology analysis. B: 11 core target genes were obtained from 41 common genes by setting a threshold through the Centiscape2.2 plug-in in Cytoscape3.10.1 software. C: Molecular docking results of PSE2 with the active sites of these 11 core targets. D: 2D and 3D images of PSE2 docking with STAT3 protein.

[0067] from Figure 3 It can be seen that PSE2 can stably bind to STAT3 protein. Figure 3 A: Comprehensive results of molecular dynamics simulation of the interaction between PSE2 and STAT3 protein. B: The entire trajectory of the interaction between PSE2 and specific amino acids of STAT3 protein. C: Schematic diagram of the interaction between PSE2 and STAT3 protein residues. D: The CETSA method was used to detect the thermal stability of STAT3 in MDA-MB-231 cells before and after the action of 0.75μM PSE2 at different temperatures.

[0068] from Figure 4 It can be seen that STAT3 is the key target of PSE2 in inhibiting TNBC cell invasion and migration. Figure 4 A: Transwell assay to detect the invasion and migration levels of MDA-MB-231 cells in the control group and STAT3 knockdown group treated with 0.75 μM PSE2. B: Figure 4 Results in A were quantified: **P < 0.01, compared with the control group. NS indicates no significant difference.

[0069] Example 3

[0070] PSE2 significantly inhibited p-STAT3 (Tyr 705 ) and STAT3 nuclear transcription.

[0071] The experimental method is as follows:

[0072] First, Western blot was used to detect p-STAT3 (Tyr 705 )、p-STAT3(Ser 727 ) and STAT3 protein levels. As STAT3 is a transcription factor that binds to specific DNA response elements to regulate target gene expression, we transiently transfected HEK-293T cells with low STAT3 expression with pGL3-STAT3, STAT3C, and Renilla luciferase plasmids, and further explored whether PSE2 inhibited STAT3-dependent transcriptional activation through luciferase gene reporter experiments.

[0073] 1. Western blot detection of p-STAT3 (Tyr 705 )、p-STAT3(Ser 727 ) and STAT3 protein levels:

[0074] After incubation with a certain concentration of PSE2 for 48 h, TNBC cells were lysed and quantified. Proteins were separated by 12.5% ​​SDS-polyacrylamide gel electrophoresis, and the membranes were transferred to PVDF membranes activated with methanol at 100 V for 2 h. The membranes were blocked with 5% skim milk at room temperature for 1 h. 705 )、p-STAT3(Ser 727 ), STAT3 primary antibody and horseradish peroxidase-labeled secondary antibody, and the protein bands were visualized and analyzed using a protein developer.

[0075] 2. Dual luciferase reporter gene assay:

[0076] HEK-293T cells were co-transfected with 50ng pGL3-STAT3, 50ng STAT3C and 40ng Renilla luciferase plasmids carrying reporter genes as internal references. After the cells stably expressed the STAT3 reporter gene, different concentrations of PSE2 were added for 24h. The cells were lysed and the luciferase activity was detected within 24h using a dual-luciferase reporter gene assay kit.

[0077] The experimental results are as follows:

[0078] We investigated the effect of PSE2 on STAT3 phosphorylation in HS-578T and MDA-MB-231 cells. 705 Phosphorylation is closely related to the nuclear function of STAT3, and Ser 727 Phosphorylation regulates the activity of the mitochondrial electron transport chain. Unlike many STAT3 inhibitors, PSE2 also significantly inhibits STAT3 Tyr705 and STAT3 Ser727 Phosphorylation (P<0.05) Figure 5 A). STAT3, as a transcription factor, binds to specific DNA response elements to regulate the expression of target genes. We further studied whether PSE2 inhibits STAT3-dependent transcriptional activation by luciferase gene reporter experiments. HEK-293T cells with low STAT3 expression were transiently co-transfected with pGL3-STAT3, STAT3C, and Renilla luciferase plasmids. Compared with the 0μM PSE2 treatment group, the luciferase activity of cells treated with different concentrations of PSE2 was lower, indicating that PSE2 significantly inhibited STAT3 transcriptional activity (P<0.05) ( Figure 5 B).

[0079] from Figure 5 It can be seen that PSE2 significantly inhibited p-STAT3 (Tyr 705 ) and STAT3 nuclear transcription. Figure 5 A: After PSE2 was applied to HS-578T and MDA-MB-231 cells for 24 h, the expression of p-STAT3 (Tyr 705 )、p-STAT3(Ser 727 ) and STAT3 protein levels. B: STAT3C, pGL3-STAT3 promoter and Renilla luciferase (as reference) plasmids were transiently co-transfected into HEK-293T cells, and luciferase activity was detected 24 hours after PSE2 treatment according to the above method. *P<0.05, **P<0.01, the difference was statistically significant compared with the 0μM PSE2 treatment group. NS indicates no significant difference.

[0080] Example 4

[0081] PSE2 inhibits p-STAT3 (Ser 727 ) and mitochondrial oxidative phosphorylation

[0082] The experimental method is as follows:

[0083] TNBC cells were seeded on cell culture plates. After a period of PSE2 treatment, oligomycin (phosphorylation inhibitor), FCCP (mitochondrial oxidative phosphorylation uncoupler) and antimycin A + rotenone (mitochondrial respiratory chain inhibitor) or glucose, oligomycin and 2-deoxy-D-glucose (glycolysis inhibitor) were injected in sequence. The effect of PSE2 on STAT3 function in mitochondria was evaluated by oxygen consumption rate (OCR) and extracellular acidification rate (ECAR, glycolysis index) using Seahorse XFe96 analyzer.

[0084] Mitochondrial Bioenergetics Analysis:

[0085] Mitochondrial bioenergetics were assessed using OCR and ECAR using the Seahorse XFe96 analyzer. OCR reflects mitochondrial oxidative phosphorylation. 4MDA-MB-231 cells were seeded on a cell culture plate. After 1 h of PSE2 treatment, the medium in the plate was replaced with a newly configured detection medium through the instrument fluid replacement program. Then, after basal respiration, oligomycin, FCCP, and antimycin A + rotenone were injected in sequence according to the manufacturer's protocol to measure the capacity of ATP-associated respiration and backup respiration. ECAR reflects glycolysis. In this experiment, the cell density per well and the PSE2 treatment time were consistent with the OCR measurement experiment. Glucose, oligomycin, and 2-deoxy-D-glucose were injected in sequence to observe the cellular glycolysis level and the ability of the cells to restore glycolysis.

[0086] The experimental results are as follows:

[0087] First, the effect of PSE2 on the two main energy production pathways of TNBC cells (mitochondrial oxidative phosphorylation and glycolysis) was studied. Oxygen consumption rate (OCR) and ECAR are indicators of oxidative phosphorylation and glycolysis, respectively. Figure 6 As shown in A, PSE2 inhibited the oxidative phosphorylation level in TNBC cells in a concentration-dependent manner. To prove whether the above inhibitory effect is related to STAT3, we constructed MDA-MB-231 cells with stable STAT3 knockdown. The oxidative phosphorylation level of STAT3 stable knockdown cells was significantly inhibited ( Figure 6 B). PSE2-treated STAT3 stably knocked-down MDA-MB-231 cells did not show significant inhibition of oxidative phosphorylation ( Figure 6 C). However, PSE2 had no significant effect on glycolysis in MDA-MB-231 cells ( Figure 6 D).

[0088] Figure 6 PSE2 inhibited p-STAT3 (Ser 727 ) and mitochondrial STAT3-dependent oxidative phosphorylation. Figure 6 In the figure, A: The oxygen consumption rate was measured using a Seahorse XF96 extracellular flux analyzer, and it was found that the OCR of MDA-MB-231 cells treated with 0.75-1.5μM PSE2 was inhibited. B: Knockdown of STAT3 inhibited the oxygen consumption rate of MDA-MB-231 cells. C: The oxygen consumption rate of STAT3 knockdown MDA-MB-231 cells before and after PSE2 treatment was measured. D: The extracellular acidification rate of MDA-MB-231 cells treated with PSE2 was measured.

[0089] Example 5

[0090] In this example, an experiment was conducted to investigate the inhibition of lung and liver metastasis of TNBC in mice by PSE2.

[0091] The experimental method is as follows:

[0092] Thirteen female immunodeficient (nu / nu) nude mice (18-22 g) were purchased from Jiangsu Huachuang Xinnuo Pharmaceutical Technology Co., Ltd. and housed in the specific pathogen-free facility of the Experimental Animal Center of Southwest Medical University. 6 Sterile human MDA-MB-231 cells were slowly injected into nude mice via the tail vein to construct a mouse TNBC lung and liver metastasis model. The mice were randomly divided into 2 groups: model group (n=7) and PSE2 group (n=6). PSE2 (5 mg / kg) group: 5 mg / kg of PSE2 was intraperitoneally injected every other day until the end of the experiment. Model group: an equal volume of normal saline was intraperitoneally injected every other day until the end of the experiment. The mice were fed a healthy diet and drank water every day and their general signs were observed. The experimental period was 31 days. After the experiment, the mice were killed, and the TNBC lung and liver metastases of the mice were isolated. At the same time, the organ tissues such as the heart and kidney of the mice were obtained. They were fixed with 4% paraformaldehyde and stained with hematoxylin-eosin (HE) to detect the pathological structural changes of tumor metastases. The pathological changes of PSE2 on multiple normal organ tissues of mice in each group were explored, so as to evaluate the toxic effects of PSE2. The number of tumor metastases in the lung and liver metastases was detected. This study was reviewed and approved by the Animal Research Ethics Committee of Southwest Medical University (approval number: 20240305-005).

[0093] The experimental results are as follows:

[0094] We established a nude mouse model of MDA-MB-231 cell lung and liver metastasis to explore the therapeutic effect of PSE2 on TNBC lung and liver metastasis mice. The results showed that no significant changes in body weight or other toxic signs were observed after PSE2 treatment ( Figure 7 A). After 31 days of the experiment, the mice were killed and it was found that PSE2 significantly inhibited the lung and liver metastasis of TNBC cells and reduced the number of lung and liver metastatic foci ( Figure 7 B-7E). In addition, intraperitoneal injection of 5 mg / kg PSE2 every other day until the end of the experiment did not cause obvious organic damage to the mouse heart and kidney tissues ( Figure 7 F), indicating that PSE2 has less toxic side effects.

[0095] Figure 7 PSE2 was shown to effectively inhibit lung and liver metastasis of TNBC in mice. Figure 7A: Body weight changes of mice in the model group (n=7) and PSE2 treatment group (n=6). B: HE staining of lungs in mice in the model group and PSE2 treatment group. C: Number and quantification of lung metastases in mice in the model group (n=7) and PSE2 treatment group (n=6). D: Number and quantification of liver metastases in mice in the model group (n=7) and PSE2 treatment group (n=6). E: HE staining of livers in mice in the model group and PSE2 treatment group. F: HE staining of organ tissues such as heart and kidney in mice in the model group and PSE2 treatment group: *P<0.05, **P<0.01, the difference was statistically significant compared with the model group.

[0096] In the above experiments, SPSS13.0 statistical software was used for data analysis. Data related to cell lines were repeated at least three times and expressed as Mean±SD. One-way analysis of variance and LSD post hoc tests were used to evaluate the differences between multiple groups (if the variance was homogeneous), otherwise Dunnett's T3 test was used for multiple group comparisons. The results of animal experiments were compared between two groups using Student's T test. P<0.05 was considered statistically significant.

[0097] Finally, it should be noted that the terms "comprises," "includes," or any other variations thereof are intended to cover non-exclusive inclusion, such that a process, method, article, or apparatus that includes a series of elements includes not only those elements, but also other elements not explicitly listed, or also includes elements that are inherent to such process, method, article, or apparatus.

[0098] Although the preferred embodiments of the present invention have been described, those skilled in the art may make other changes and modifications to these embodiments once they have learned the basic creative concept. Therefore, the appended claims are intended to be interpreted as including the preferred embodiments and all changes and modifications that fall within the scope of the present invention.

[0099] Obviously, those skilled in the art can make various changes and modifications to the present invention without departing from the spirit and scope of the present invention. Thus, if these modifications and variations of the present invention fall within the scope of the claims of the present invention and their equivalents, the present invention is also intended to include these modifications and variations.

Claims

1. Use of a STAT3 dual phosphorylation inhibitor in the preparation of a drug for preventing or treating triple-negative breast cancer, characterized in that: The STAT3 dual phosphorylation inhibitor includes scutellaria baicalensis saponin E2 and / or a pharmaceutically acceptable salt thereof, and the structural formula of scutellaria baicalensis saponin E2 is as follows:

2. Use of Pulsatilla saponin E2 and / or its pharmaceutically acceptable salt as a STAT3 dual phosphorylation inhibitor in the preparation of a drug for inhibiting the growth or metastasis of triple-negative breast cancer cells.

3. Effect of Pulsatilla saponin E2 and / or its pharmaceutically acceptable salt on inhibiting STAT3 protein Tyr 705 and / or Ser 727 Application in phosphorylation.

4. Use of Pulsatilla saponin E2 and / or its pharmaceutically acceptable salt in inhibiting STAT3 nuclear transcription and / or STAT3-dependent mitochondrial oxidative phosphorylation.

5. Use of Pulsatilla saponin E2 and / or its pharmaceutically acceptable salt as and / or in the preparation of a STAT3 dual phosphorylation inhibitor.

6. The use according to claim 5, characterized in that: The STAT3 dual phosphorylation inhibitor includes inhibiting STAT3 protein Tyr 705 and Ser 727 Reagents for site phosphorylation.

7. A drug for preventing or treating triple-negative breast cancer, characterized in that: The active ingredients of the medicine include pulsatilla saponin E2 and / or its pharmaceutically acceptable salt.

8. A drug for inhibiting the growth or metastasis of triple-negative breast cancer cells, characterized in that: The active ingredients of the medicine include pulsatilla saponin E2 and / or its pharmaceutically acceptable salt.

9. A STAT3 dual phosphorylation inhibitor, characterized in that: The active ingredient of the STAT3 dual phosphorylation inhibitor includes pulsatilla saponin E2 and / or a pharmaceutically acceptable salt thereof.

10. A STAT3 dual phosphorylation inhibitor according to claim 9, characterized in that: The STAT3 dual phosphorylation inhibitor includes inhibiting STAT3 protein Tyr 705 and Ser 727 Reagents for site phosphorylation.

Citation Information

Patent Citations

  • Triterpenoid saponin compounds with antitumor effects

    CN102627683A

  • Pulchinenoside coupling derivatives and application thereof in preparation of antitumor drugs

    CN106749488A

  • Application of STRAP inhibitor in preparation of product for treating invasive breast cancer

    CN113244401A

  • Small molecule STAT3 inhibitor for treating triple negative breast cancer

    WO2023159048A2

Cited By

  • Application of a selective METTL16 inhibitor in the preparation of drugs for non-small cell lung cancer

    CN123059065A